by Advize Admin | Oct 17, 2019 | Fraud, FWA, Healthcare
Retired OIG Special Agent and Advize’s Director of Litigation & FWA Support will be stepping in each week to examine current fraud trends from the lens of an investigator. Stay tuned for weekly insights, updates, and information on healthcare’s most expensive...
by Advize Admin | Aug 7, 2019 | Fraud, Healthcare
Recently, the State of New Jersey, Division of Consumer Affairs (the department that administers, among other things, the Prescription Monitoring Program [PMP]), reclassified a drug known as Gabapentin. In reclassifying the drug, it is now considered a scheduled drug...
Recent Comments